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THE IMPACT OF DELAY TO FIXATION ON PD-L1 EXPRESSION 
IN HUMAN TISSUE 
BERNARD JAMES VARIAN 
ABSTRACT 
 The effects of tissue preservation techniques are known to have meaningful 
impact on diagnostic and prognostic variables. This study aims to evaluate and improve 
the quality of biospecimens utilized in cancer research. Protein Death Ligand 1 (PD-L1) 
is a cell surface molecule with an important role for immune suppression. Its utility lies 
within providing a basis for limiting the immune response.  We aimed to evaluate the 
expression levels of PD-L1 in tissues that had varying lengths of delay to fixation. 21 
placenta, renal, and colon surgical specimens were collected and divided into delay to 
fixation cohorts.  Samples were then evaluated through Hematoxylin and Eosin (H and 
E), PD-L1 Immunohistochemistry (IHC), and for the colon samples Microsatellite 
Instability (MSI) Status. A total of 75% of slides were positive for PD-L1 expression. In 
relation to Placenta all were positive for PD-L1 expression. While colon samples were 
41.25% positive for PD-L1 expression. Finally 49.5% of renal samples were positive for 
PD-L1 expression. Of the three colon samples one was MSI Low status while the 
remaining were Microsatellite Stable (MSS). PD-L1’s status as a utile biomarker for 
prognostic and diagnostic reasons remains uncertain. The stability of PD-L1 expression 
across tissue type and sample delay shows the stability of the biomarker. Therefore our 
work shows that a delay while significant in affecting other biomarkers does not 
significantly alter PD-L1 expression.   
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PURPOSE 
Given the increasing understanding of the tumor microenvironment along with the 
evasion mechanisms of the immune system by cancer, it is increasingly important to 
understand if Programmed Death Ligand 1 (PD-L1) expression is significantly changed 
in tissue not fixed within an appropriate amount of time. This study aims to look at the 
impact of delay to fixation on the expression of PD-L1 in renal cancer, colon cancer, and 
placenta. Another aim is to provide reliable interpretive analysis of PD-L1 
immunohistochemistry (IHC) expression.  
The placenta is a tissue where paternal antigens can pose a threat to fetal survival. 
For the purposes of mammalian survival there are many mechanisms in place to provide 
immune tolerance (Alijotas-Reig, Llurba, & Gris, 2014; Williams, 2012). One proposed 
mechanisms for immune tolerance is the PD-1/ PD-L1 axis.  Expression of PD-L1 on 
trophoblastic populations is low during the first trimester and increases during gestation 
(Petroff, Kharatyan, Torry, & Holets, 2005). The trophoblast is the portion of the placenta 
that comes in direct contact with the maternal human blood supply (Aplin, 1991). Due to 
the important role of supplying blood flow and nutrients to the fetus (Pollheimer & 
Knofler, 2012), it is clear that foreign material will be targeted by the maternal immune 
system. PD-L1 expression controls the population of lymphocytes that would attack 
antigens foreign to the mother (Taglauer, Yankee, & Petroff, 2009). The expression of 
PD-L1 enabled the placenta to be a good positive control for the experiments and a good 
model tissue to test the effect of delay to fixation on PD-L1 expression.  
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To test the PD-L1 in other tissues we used colorectal and renal cancer samples. 
Colorectal cancer is the second leading cause of cancer related mortality in the United 
states, being the third most common cancer in men and women (Edwards et al., 2014). 
Notably the incidences of mortality have declined over the past decade likely due to 
preventive care measures involving fecal occult blood tests and colonoscopies (Chan & 
Giovannucci, 2010). Given the bacterial load in the gut it should come as no surprise that 
the microbiota is shown to affect the response to cancer treatments (Iida et al., 2013). 
Even more attention has shown that the diversity of the microflora decreases in patients 
found to have colorectal cancer (Ahn et al., 2013). Additionally cancers, including 
colorectal cancer, found to have mismatch repair (MMR) gene deficits benefited from 
Anti-PD-1 therapy (Le et al., 2015). MMR deficiencies lead to clusters of mutations that 
become known as microsatellite instable (MSI), while MMR proficient are known as 
microsatellite stable (MSS). 
Kidney cancer was the third specimen type analyzed and can come in several 
forms like renal cell carcinoma, transitional cell carcinoma, renal adenoma, renal 
sarcoma, nephroblastoma, onncocytoma, angiomyolipoma (Vogelzang & Stadler, 1998). 
Interestingly, kidney cancer mortality is twice as high in men than women (Lucca, Klatte, 
Fajkovic, de Martino, & Shariat, 2015). Although as a trend, mortality has fallen over the 
past decade (Hatakeyama et al., 2016), which is likely due to the incidental finding of 
kidney cancer during abdominal imaging. The incidental findings can account for the 
increase in renal cancer incidence since increased imaging in 1997 with the rate leveling 
off in 2008 ("Kidney Cancer. Principles and Practice," 2016). Clear cell renal carcinoma 
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has seen the von Hippel-Lindau mutation leading to increased PD-L1 expression (Stone, 
2016). Knowing the PD-L1 status of cancers can have important implications for 
identifying targetable mutations; it becomes important to test for PD-L1 and to know if 
expression changes due to delays in fixation.  
To test the expression of PD-L1 Immunohistochemistry (IHC) was used. IHC is 
an important tool used to characterize cells and tissues. Individual IHC markers or panels 
of IHC markers can be used to help characterize the tissues. The markers can provide 
important molecular information about the tissue that can be important for prognosis, 
treatment, or post-treatment evaluation. (Zaha, 2014).  The choice of markers depends on 
preference and financial resources. Another consideration is the duration of fixation. In 
breast cancer, the underfixation of benign glands can produce an artifact morphology that 
can be mistaken for carcinoma. Standard protocols for HER2 gene detection require the 
tissue to undergo formalin fixation of more than 6 hours but less than 48 hours (Gown, 
2008). It is important to reduce laboratory variation and maintain conformity for the 
important value the information provides for patient health outcomes. This emphasizes an 
example where results can vary based on the preparation, reagents, antibodies, and other 
methods involved. 
This study first aims to see the effects of delay to fixation on PD-L1 expression in 
various tissues. Secondly the study takes the approach of standardizing the IHC analysis, 
thereby minimizing variation from person to person and laboratory to laboratory 
addressing the research needs presented by the National Cancer Institute (NCI). This 
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work is performed with the intention of providing quality assurance to a best practice 
regarding the interpretation of high quality biospecimen analysis.  
 NCI directs industry guidelines, having research interests in cancer genomics, 
epigenomics, proteomics, and nanotechnology. Given the large public health impact of 
these interests NCI has established The Cancer Human Biobank (caHUB) spurred by a 
need noticed in The Cancer Genome Atlas (TCGA) study. The caHUB serves to 
standardize biospecimen processes, while TCGA is meant to map changes due to cancer 
in the information stored in tissues. TCGA showed the need for statistically significant 
numbers of quality controlled biospecimens that are properly consented and contain the 
appropriate clinical information.  
 Due to the reliance on high quality and standardized biospecimens, NCI funded 
research programs like TCGA, found that 65% of the tumor biospecimens were 
inadequate for research. The caHUB was established to create and disseminate standard 
operating procedures aimed at providing quality samples for large-scale research.  This 
provides the basis for the development of therapies, diagnostics, and basic research. 
TCGA, which is no longer collecting samples, utilizes high throughput analysis of 
deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) from tumor cells with patient 
matched normal cells.  
In order to support high throughput analysis from biospecimens, the caHUB was 
established to support biospecimens science activities by gathering specialized 
biospecimens and data. This work develops an infrastructure for collaboration and 
standards for Standard Operating Procedures (SOPs) with the intent of enabling the 
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community to collect biospecimens fit for research through collection, processing, and 
storage.  
Once the samples are of known quality the work can be made on identifying the 
changes in genome that lead to cancer. More importantly the information can lead to an 
understanding of how these changes interact to drive the disease. Thereby identifying 
ways to prevent, detect, and treat the disease.  
By understanding the molecular basis of these diseases, it is necessary to acquire 
the samples with a control. The extraction of DNA or RNA from the tissue to be rapidly 
sequenced can be interpreted and integrated to provide the data swiftly to the community 
through patient protected databases.  
Through learning from TCGA it was seen that there was a need to improve the 
quality of biospecimens for research and human advancement. caHUB helps maximize 
the role human samples can play in biomedical research. The work from this project 
helps exhibit the way samples are handled, through collection to processing and storage, 
which can have an effect on outcomes. With the outcomes being the progress in 
biomedical research through the use of biospecimens, where a known quality is 
important. Most importantly NCI is involved in biobanking as it comes from the 
consenting public and is intended to benefit the public. By developing the infrastructure 
for collaboration and sample procurement, the public health benefits can be met.  
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INTRODUCTION 
Hygiene Hypothesis 
 The hygiene hypothesis describes the phenomenon seen in economically 
developed countries where a higher frequency of allergies and autoimmune disorders are 
seen as compared to developing countries. The higher standards of living and lower rates 
of childhood infection are thought to increase immune dysregulation (Cooper, 2009; 
Wilson & Maizels, 2004). Microbial exposure at an early age can help develop proper 
immune system development (McSorley & Maizels, 2012). The in utero effects of 
environmental factors is gaining recognition as affecting epigenetic changes that can alter 
gene function and the immune response in a diseased state (Hawrylowicz & Ryanna, 
2010).  
 The hygiene hypothesis suggests that early life exposures prime the immune 
system to respond to certain pathogens in a healthy way. This is correlated by a lack of 
exposures leading to hyper-reaction and inappropriate immune responses later in life. The 
theory of early life exposure and priming of the immune system has led some to associate 
the parasitic eradication with diseases such as asthma and inflammatory bowel disease 
(IBD). Some of the clinical trials involve live parasite infection in disease states like IBD 
(Chrohn’s, celiac, and ulcerative colitis) autoimmune diseases like multiple sclerosis, and 
allergic diseases like seasonal rhinitis (McSorley, Hewitson, & Maizels, 2013).    
 Public health initiatives, like vaccination and sanitation, have been instrumental in 
decreasing human mortality over the past century (Armstrong, Conn, & Pinner, 1999). 
This clean environment is not what humans evolved to live in, resulting in a decreased 
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parasite burden. Some microbes have evolved to make a protein that down-regulates 
Type 2 responses preventing the immune system from attacking the invader (Melendez et 
al., 2007). Understanding the role of evolutionary processes can allow for progress in 
treating autoimmune and immune dysfunction diseases. 
Beneficial microbes induces Interleukin (Il) -10 secretion through regulatory B 
cells, which are known to play a role in down-regulating inflammation (Girgis, Gundra, 
& Loke, 2013). The bystander suppression of autoimmune diseases is likely the response 
of the increased number of these regulatory cells (Correale & Farez, 2011; Wiria, 
Djuardi, Supali, Sartono, & Yazdanbakhsh, 2012). Less prevalence of allergies and 
autoimmune diseases in underdeveloped countries is linked to infection of parasites. This 
is why microbes are being investigated as treatments to diseases like autism, asthma, 
allergic rhinitis, and inflammatory bowel disease (Girgis et al., 2013).  
 
An Overview of Immune Responses 
 It is thought that each microbe individually adapts with the host to have a distinct 
mechanism. Microbes can inhibit the T Helper cells (Th), specifically Th1/Th17 
mediated inflammation and Th2 dependent pathologies, which allows them to have a 
useful role in correcting most immunogenic disease (McSorley et al., 2013). The type two 
response (Th2) of the immune system is likely used to limit the number of parasites 
living in the host and to repair the epithelium damaged by the microbe (Girgis et al., 
2013). It is common for microbes to suppress the inflammatory (Th1) pathway. The 
suppression of early innate immune responses and the up-regulation of T regulatory cells 
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(Tregs) allows for a significant amount of tolerance to the microbe and other allergic 
antigens (McSorley et al., 2013).  
An optimal host immune system can expel large parasites, facilitate wound and 
tissue repair, and limit inflammation associated with chronic parasitic infections (Wolff, 
Broadhurst, & Loke, 2012). In the intestines dendritic cell dendrites cross the epithelial 
lining to sample the environment, thereby directly interacting with the microbe. Microbes 
are also thought to alter the microbiome, which has known implications on both health 
and disease (Walk, Blum, Ewing, Weinstock, & Young, 2010).  
 Additional protections spurred from microbes include increased goblet cell 
differentiation and producing more mucus, which is important in strengthening and 
repairing the epithelial barrier of the bowels (Wolff et al., 2012). Microbes also activate 
macrophages to adopt an anti-inflammatory tissue repair function. The type two immune 
response causes B cells to secrete Immunoglobulin (Ig) E, which activates basophils, 
eosinophils, and mast cells that amplify the Type two response by secreting more Il-4 
(Allen & Wynn, 2011). Finally, microbes stimulate the expression of PD-L1 as ways to 
dampen the immune response (Sivan et al., 2015).  
 The hygiene hypothesis provides the framework of how immune regulation 
processes evolved over time. The hygiene hypothesis is the explanation of how the host 
interacts with its environment, with immune and exposure interactions eliciting responses 
that affect the immune system and homeostasis of the host. The implications of consistent 
IHC analysis allow for the potential use of PD-L1 expression as a biomarker indicating 
positive or negative health outcomes.  
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Tumor Immunity Cycle and the PD-1/PD-L1 Checkpoint Pathway 
The tumor immunity cycle is the body’s normal mechanism for dealing with 
cancer. The cycle begins with tumor cells producing mutated antigens that get picked up 
by dendritic cells. The dendritic cells present the antigen to the T cell and stimulate the 
activation of cytotoxic T lymphocyte cells (CTLs). The activated CTLs then travel to the 
tumor and infiltrate the tumor environment, where they recognize antigen and bind to the 
cancer cells. The bound effector T cell will then release cytotoxins inducing apoptosis in 
the target cancer cell. These dying cancer cells release further tumor associated antigens 
propagating the tumor immunity cycle (D. S. Chen & Mellman, 2013). 
T cells are activated by an antigen specific receptor along with another T cell 
costimulatory pathways, which plays a role in the balance of protective immunity and 
tolerance. There are both positive and negative costimulatory signals yet in the absence of 
the costimulatory signal, a T cell will remain unresponsive to antigenic stimulation 
(Schwartz, Mueller, Jenkins, & Quill, 1989). Costimulation affects effector, memory, 
regulatory T cells, and naïve T cells.  
The inflammatory milieu regulates the differentiation of immune cells and 
specifically the expression of PD-L1 and PD-L2 with type 1 and 2 interferons (INF) and 
Tumor necrosis factor (TNF) alfa inducing PD-L1 expression in T and B cells, 
endothelial cells, and epithelial cells (Keir, Butte, Freeman, & Sharpe, 2008). Il-2, IL7, 
IL15 increase PD-L1 expression on human T cells where IL-21 stimulates PD-L1 
expression in B cells from peripheral blood mononuclear cells, whereas IL-10 stimulates 
PD-L1 expression in monocytes (Kinter et al., 2008). 
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Interestingly PD-L1 has been shown to both inhibit T cell proliferation and 
cytokine release as well as enhance T cell activation. This is thought to be due to the PD-
L1 inhibition of negative signaling (Francisco, Sage, & Sharpe, 2010). Tregs regulate 
inflammation by suppressing the T effector (Teff) cells. And naïve T cells can be turned 
into Tregs with the transforming growth factor (TGF)-Beta and IL-2 (W. Chen et al., 
2003). It is in this way that PD-1 and its ligands limit Teff cells and promote Tregs. In 
sites of immune privilege like the placenta, PD-L1 plays a role in promoting the 
generation of Tregs (Francisco et al., 2009).  PD-L1 is expressed in many tumors with 
unfavorable outcomes (Driessens, Kline, & Gajewski, 2009) as well as forkhead box P3 
(Foxp3+) Tregs, The PD-L1 expression in the tumor is thought to promote the induction 
of Tregs to limit immune attacks. 
 
An Introduction to PD/ PD-L Proteins 
 There are five human isoforms of PD-1, which is a type 1 transmembrane protein. 
The extracellular portion is an IgV sequence while the cytoplasmic portions contain a 
ITIM (Immuno-receptor tyrosine-based inhibitory motif) and an ITSM (immune-receptor 
tyrosine-based switch motif) which is essential for the inhibition of T cell receptor (TCR) 
signaling (Okazaki & Wang, 2005). PD-L1 is a cell surface protein.   
PD-L1 expression can be regulated at the post-transcriptional level through 
alternative splicing and modulation of the PD-L1 isoform, which are thought to have an 
effect on the outcome of immune responses in the periphery (Y. B. Chen, Mu, Chen, & 
Huang, 2014). Important to cancer immunology PD-L1 is expressed in carcinomas of the 
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lung, ovary, colon, melanoma, and leukemic cells (Dong et al., 2002). PD-L1 is highly 
expressed on Tumor infiltrating macrophages, tumor cells, and antigen presenting cells 
(APCs) in the tumor microenvironment (Y. B. Chen et al., 2014). Tumor cells upregulate 
PD-L1, which dampens the CTL attack. This upregulation could be a result of the pro-
inflammatory environment presented by tumor infiltrating lymphocytes (TILs) such as 
INF-gamma secretion which is known to upregulate PD-L1 (Liechtenstein et al., 2012). 
 
Immune Resistance Hypotheses 
 The PD-1/ PD-L1 axis has a suppressive function in T cells, especially in the 
tumor microenvironment (Zou & Chen, 2008). Normal PD-L1 expression is seldom in 
normal tissue except places like the tonsil, placenta (Petroff, Chen, Phillips, & Hunt, 
2002) and macrophages in the lung and liver (Dong et al., 2002). Cancer cells express 
high amounts of PD-L1 in focal areas where INF-gamma is secreted by T cells (Dong et 
al., 2002), which is known to promote the T cell activity through antigen processing and 
presentation (Boehm, Klamp, Groot, & Howard, 1997; D. S. Chen & Mellman, 2013). In 
vitro studies have shown that PD-L1 tumor cells could eliminate T effector cells through 
apoptosis and this could be blocked by the addition of an anti-PD-L1 clone [32]. INF-
gamma is mainly produced by cells of a hematopoietic origin especially T cells. It is 
reasonable to assume that PD-L1 is upregulated in response to cancer induced 
inflammation.  
The adaptive resistance is initiated by the recognition of tumor antigens by TIL’s. 
Tumor antigen is picked up and presented by neutrophils, macrophages, dendritic cells 
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(DC’s) and upon recognition by the T cell release INF-gamma inducing PD-L1 
upregulation, which explains why PD-L1 is expressed focally and in areas where T cells 
are located (Taube et al., 2012). Induced PD-L1 in the tumor microenvironment is 
intended as a negative feedback mechanism to suppress tumor immunity. INF-gamma is 
a major driver of PD-L1 expression in the tumor microenvironment. However it should 
be noted there are cases of INF-gamma independent PD-L1expression in tumors 
(Velcheti et al., 2014). It’s been shown that a loss of phosphatase and tensin homolog 
(PTEN), constitutive anaplastic lymphoma kinase (ALK) signaling, and Epithelial 
Growth factor receptor (EGFR) mutations can lead to the upregulation of PD-L1 on 
cancer cells (Akbay et al., 2013; Parsa et al., 2007).  
In addition to the adaptive response hypothesis there is the innate response 
hypothesis that centers around the abnormal signaling or oncogene upregulation of PD-
L1 with examples being glioblastoma and lymphoma (Parsa et al., 2007). Taube et al. 
explains that PD-L1 is expressed after exposure to tumor infiltrating lymphocytes (Taube 
et al., 2012). 
 
Tumor differentiation status and pd-l1 expression 
There is conflicting evidence supporting the association between differentiation 
status of tumors and the expression of PD-L1. In our cancer samples there appears to be a 
statistically insignificant pattern of increased staining in poorly differentiated cancers. 
PD-L1 expression was found not to be associated with the differentiation status (Z. Chen 
et al., 2016) suggesting little use in predicting prognosis. However additional studies 
 13 
show that there is increased PD-L1 expression in Tumor Infiltrating lymphocytes found 
in samples of poorly or moderately differentiated cancers indicating a potentially positive 
response from PD-L1 targeted therapies (Mo et al., 2016).  Rosenbaum et al. found that 
PD-L1 expression was associated with poor differentiation and Cluster of differentiation 
8 positive (CD8+) TIL’s indicating an adaptive resistance response that could benefit 
from therapies (Rosenbaum, Bledsoe, Morales-Oyarvide, Huynh, & Mino-Kenudson, 
2016).  
 
Treatments Designed to Target the PD/PD-L Axis 
Immunotherapies designed to target the PD/PD-L axis are based on the idea of 
blocking the tumor’s mechanisms of evading the immune system. Therapeutic 
approaches range from cytokines, vaccines, cellular therapies, and checkpoint inhibitors. 
Immune checkpoint inhibitors target several pathways like the Programmed death 
PD/PD-L axis and the cytotoxic T lymphocyte antigen 4 (CTLA-4). The CTLA-4 
pathway tends to have more adverse reactions in response to tolerance to normal tissue.  
With the knowledge of the PD-1/PD-L1 axis anti-PD therapy has led to 
significant benefits in terms of tumor regression and improving survival. The PD therapy 
has been shown to have durable effects and tolerable side effects in multiple tumor types. 
This is distinct from personalized or tumor type specific therapy. There are not many 
significant differences among the anti-PD-1/PD-L1 monoclonal antibodies (mAbs) as 
reported in the trials. However there are no head to head comparisons comparing the 
agents that are approved PD pathway inhibitors. The major function of PD pathway is to 
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control ongoing inflammatory responses and prevent the spread of inflammation. This 
differs from inhibitors targeting other mechanisms tumors use to evade the immune 
system that work through the systemic regulation of autoreactive T cell responses like 
other immune checkpoints like CTLA-4. CTLA-4 or Cytotoxic T-Lymphocyte associated 
protein 4 suppresses T cell responses to self-antigens by controlling Treg activity.    
Food and Drug Administration (FDA) approved and pending PD-1 inhibitors 
include: nivolumab approved for melanoma (Weber et al., 2013), non-small cell lung 
cancer(Sunshine & Taube, 2015), renal cell carcinoma(Motzer et al., 2015), with trials 
completed for Hodgkins lymphoma(Ansell et al., 2015), small cell lung cancer(Sunshine 
& Taube, 2015), hepatocellular carcinoma(Sunshine & Taube, 2015), and ovarian 
cancer(Hamanishi et al., 2015). Pembrolizumab approved for melanoma, non-small cell 
lung cancer, with trials completed in small cell lung cancer, head and neck cancer, 
urothelial cancer (Sunshine & Taube, 2015). Pidilzumab for trials completed with 
melanoma (Sunshine & Taube, 2015).  
FDA approved and pending PD-L1 inhibitors include: MEDI4736 for trials 
completed with non-small cell lung cancer and head and neck cancer (Sunshine & Taube, 
2015).  BMS-936559 for trials completed with melanoma and non-small cell lung cancer 
(Brahmer et al., 2012). Atezolizumab for trials completed in bladder cancer (Powles et 
al., 2014), melanoma, non-small cell lung cancer, and renal cell carcinoma (Herbst et al., 
2014).  
FDA approved PD pathway treatments report that adverse events aren’t very 
severe which include fatigue, endocrinopathologies (thyroid dysfunctions) rash, 
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pneumonitis, colitis, and hepatitis. These adverse events are able to be controlled with 
immunosuppression therapies. Many of these drugs have received break through therapy 
status from the United States Food and Drug Administration. The designation allows for 
an expedited design and approval process. Additionally another important feature of these 
immunotherapies has been the durability of the response.   
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MATERIALS AND METHODS 
Human Subject Involvement, Characteristics, and Design 
Subjects were adults having a diagnosis of colon or renal disease, undergoing 
surgery for removal of a biospecimen for diagnosis or therapy. Participants were adults 
(18-64 years), any ethnicity, both genders, and no special vulnerable populations were 
involved. Those excluded are any that do not give informed consent. Subjects will not be 
assigned into groups.  Rather, the purpose is to determine the impact of delaying fixation 
on the ability to measure pre-analytic variables of the disease state.  So all tissue was 
compared to a quality control sample taken in the same time and manner as a normal 
clinical procedure.  
Our methods included identifying patients for the study, consenting patients at the 
time of their clinical visits, collecting discard tissues, and preserving samples according 
to the study design (fixation time, delays to fixation and snap-freezing of samples). All 
work was performed at BMC. After selection tissue samples will be processed in order to 
evaluate variables. Samples will be disposed of after approval of thesis. This is described 
in Figure 1.  
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Figure 1: Study Timeline and Sample Design 
  
A. The study was designed over two months in January and February 2015. IRB approval 
occurred over the following three-month periods. The sample acquisition occurred over 
the next 7-month period with Sample analysis occurring in the remaining period. 
B. The samples were collected from surgery with the quality control sample placed 
immediately into formalin while the remaining samples were placed into humidity 
chambers to prevent the tissue from dying out until their delay time points were reached. 
The time points were 1 hour, 2 hours, 3 hours, and 6 hours post resection. The samples 
then were in formalin for a minimum of 24 hours before paraffin processing. 
 
Source of Samples 
Staff worked with the OR schedules, surgeons, and surgeons' office 
administrative staff to identify potential candidates. Once a potential candidate has been 
identified we accessed the patient's medical record, including the radiologic images, 
pathological reports and clinical notes to confirm diagnosis. Surgeons were asked not to 
recruit their patients, though they will be informed about the study. This was meant to 
segregate the therapy and research aims. 
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MATERIALS AND METHODS 
 
  
 
Human Subject Involvement, Characteristics, and Design 
Subjects are adults having a diagnosis of colon or renal disease and undergoing 
surgery for removal of a biospecimen for diagnosis or therapy. Participants are adults 
(18-64 years), any ethnicity, both genders, and no special vulnerable populations will be 
involved. Those excluded are any that do not give informed consent. Subjects will not be 
assigned into groups.  Rather, the purpose is to determine the impact of delaying fixation 
on the ability to measure pre-analytic variables of the disease state.  So all tissue will be 
compare to a quality control sample taken at the same time and treated as the normal 
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OR schedules and tumor registry were monitored to identify potential subjects. 
Each person screened was assigned a unique screening number, which was correlated 
with their name and MRN on our secure, encrypted database. No Personal health 
information were in any other forms, just the screening number. Due to the specificity of 
disease types we sought a waiver of consent for the screening to review the pathology 
and radiology reports to determine tumor size and eligibility. This was sought because the 
OR schedule were not specific enough to indicate cancer. Only the study staff (PI, Cheryl 
Spencer, Liz Duffy, Bernard Varian) had access the reports. Patients were contacted at 
one of their appointments and invited to participate in the study. 
The patients' names, MRN, and types of cancer were collected as well as the total 
number of patients screened. For excluded patients the reason were noted. Each person 
screened was assigned a screening ID indicating: Age, Exposures (e.g. drinking, 
smoking, occupation), gender, race, ethnicity, Disease Diagnosis/ normal, method of 
Diagnosis, treatments, height, weight, familial history, Received a redacted pathology 
report that includes: histologic type, grade, size, nodal status, Path TNM status and stage, 
procedure, biomarkers, outcome (death, date of last follow up, recurrence), collection 
method, comorbidity. 
The Patient's name, MRN, and types of cancer were collected as well as the total 
number of people screened. Patients who screen out will have their records destroyed 
quarterly. The type of tumor, screening number, and total number screened was retained. 
The consent was obtained by a study member, in a consultation room after the patient's 
office visit or before the surgical procedure in the registration or pre-operative area. 
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Patients were able to discuss any questions with the study member before making their 
decision to participate or not. Patients were able to have the option to withdraw their 
consent within 7 days. Consent was not required prior to eligibility screening. 
Patients enrolled in the study were identified by their Screening number and a 
limited data set (This includes: age, race, sex, treatment, diagnosis, redacted pathology 
report). Study patients were logged in a password-protected database and were only 
accessible by limited study personnel (Liz Duffy and Bernard Varian). Research Data 
was stored as a spreadsheet in a password protected folder in the Remick Folder on the 
secure Y drive. Data was stored through the duration of the study unless patients screened 
out of eligibility, when they were destroyed quarterly. The data was cleared and then 
deleted.  
Potential Risks 
The greatest risk was the loss of privacy through the release of information from 
patient health records. Patients who screen out had their records destroyed quarterly. 
Another potential risk involved the disclosure of private information: Inadvertent 
disclosure of identification was very unlikely given the nature of the databases proposed 
and the detailed SOPs employed by the BARC. Disclosure of participant information by 
subpoena or other legal means remained possible but unlikely. 
The magnitude of potential damage done to subjects by disclosure of identifying 
information was small, as participation was not expected to be associated with social 
stigma or with any legal or financial consequences. The risk of disclosure remains until 
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samples are destroyed. Operations were conducted according to the BARC SOPs, which 
protected patient confidentiality. 
A numerical code was assigned to each specimen that was not related to the 
patient and could not be tracked back to the patient, which will minimized risk associated 
with the loss of privacy. The key that links the patient information to the code was kept in 
a secure, password protected database and was only accessed by authorized personnel. 
Patients were able to request to have their collected samples destroyed prior to release 
from BMC. Information to that regards was written in the informed consent form. 
The risk to benefit ratio of this project was very low. The risk of physical patient 
harm was negligible, the risk to impaired diagnostic decision making was low since 
material will not be released to the project until the final decision was given by the 
attending pathologist. All tissue dissection will be performed under the direct supervision 
of an attending board certified pathologists. The benefits of the study were the 
appropriate use of human material in ongoing biomedical research to improve 
understanding, diagnosis, and treatment of human disease. In addition, we provided an 
infrastructure to safeguard the privacy of study participants in a comprehensive manner. 
Given these safeguards, the risk to research subjects was small. 
Humidity Chambers 
Humidity chambers were used to prevent tissue from drying out while minimizing 
tissue contact with water. Supplies necessary were gauze, water, tissue cassettes, and 
sterile specimen cups. Wet gauze was placed into tissue cassette and closed and then 
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placed into a specimen cup. Tissue for differing time points were also placed into the 
respective cups. Ensure cups have for research use only label.  
Labeling scheme used was B15-1 (this identifies Case by year) A, B, C, D or QC 
(this indicates sample time point).  T – 0, 1, 2, 3, 6. e.g. B15-1-A. This is shown in Table 
1 with the quantities of specimen case and sample time point.  
Table 1: Case and Sample Spread 
 
Fixation Time Points 
There were differing time points in order to look at the differing effects of tissue 
fixation in a single sample. Supplies needed were tissue, formalin, and histology bench 
(3rd floor, 670 Albany). Using Epic to check on status of patient. Additionally can call 1.5 
hours into procedure to circulation nurse to remind that we would like sample. In epic 
look at OR schedules, double click on patient consented, OR schedules or anesthesia.  
Consented the patient while they were in Registration, located in Newton Pavilion 
1st floor. After make two photocopies of signed form. Gave the patient one with 
telephone number and Name of consenter. Put one in patient’s folder to be found in 3rd 
floor pre-op area. Saved a third copy to go in records.  
3rd floor of Newton Pavilion was the location of resected specimen pickup. The 
sample was brought back to the histology bench, notified the pathologist on call and 
prepared for fixation. Samples were given to the histologist on duty for processing.  
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Table	2:	Dehydration	Protocol	
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Table	3:	Ethanol	to	Xylene	Protocol	
	
Specimen 0h	Timepoint 1h	Timepoint 2h	Timepoint 3h	Timepoint 6h	Timepoint Total
Abbreviation QC A B C D
Kidney 4 4 3 3 3 17
Colon 3 3 3 3 3 15
Placenta 14 14 14 14 14 70
Total 21 21 20 20 20 102
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Immersion Fixation 
10% neutral buffered formalin (NBF) is most commonly used. This fixative has 
been used unless stated otherwise.  
The ideal fixation time depends on the size of the tissue block and the type of 
tissue, but fixation between 18-24 hr seemed to be ideal for most applications. Under-
fixation can lead to edge staining, with strong signal on the edges of the section and no 
signal in the middle; over-fixation can mask the epitope. Antigen retrieval can help 
overcome this masking, but if the tissue has been fixed for a long period of time (i.e. over 
a weekend), there may be no signal even after antigen retrieval. 
After fixation, the tissue block was embedded in paraffin, then cut in a microtome 
to the desired thickness (approximately 5 microns is ideal for IHC) and affixed onto the 
slide. Tissue sections are best mounted on positively charged slides. Once mounted, the 
slides were dried to remove any water that may be trapped under the section by leaving 
the slides vertical at incubation of the slide at 60°C for a few hours.  
 
 Paraffin Tissue Processing 
 
Parrafin	Processing
Begin	with	Formalin	Fixed	Tissue
Rinse	Fixed	Tissue	in	PBS
Dehydrate	Tissue
Exchange	Ethanol	with	Xylene
Exchange	Xylene	with	Parrafin
Tissue	is	ready	for	Embedding
Solution Incubation time
50% Ethanol 10 min
70% Ethanol 10 min
80% Ethanol 10 min
95% Ethanol 10 min
100% Ethanol 10 min
100% Ethanol 10 min
100% Ethanol 10 min 
Solution Incubation time
2:1 Ethanol : Xylene 10-15 min
1:1 Ethanol : Xylene 10-15 min
1:2 Ethanol : Xylene 10-15 min
100% Xylene 10-15 min
100% Xylene 10-15 min
100% Xylene 10-15 min
Solution Incubation time
2:1 Xylene : Paraffin 30 min
1:1 Xylene : Paraffin 30 min
1:2 Xylene : Paraffin 30 min
100% Paraffin 1-2 hr
100% Paraffin 1-2 hr or overnight
Dehydration
Exchange ethanol with xylene
 Exchange xylene with paraffin.
Table 1: Ov rvi w of Parrafin Processing
Table 2: Dehydration Protocol
Table 3:Ethanol to Xylene Exchange
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After fix tion, tissue was rinsed with PBS until fixative was completely removed.  
We then followed tables 2 -4 t  obtain parafi ized tissue for embedding.  
 
 
 
Embed in fresh new paraffin and orient tissue as desired before it hardens. 
 
Parrafin	Processing
Begin	with	Formalin	Fixed	Tissue
Rinse	Fixed	Tissue	in	PBS
Dehydrate	Tissue
Exchange	Ethanol	with	Xylene
Exchange	Xylene	with	Parrafin
Tissue	is	ready	for	Embedding
Solution Incubation time
50% Ethanol 10 min
70% Ethanol 10 min
80% Ethanol 10 min
95% Ethanol 10 min
100% Ethanol 10 min
100% Ethanol 10 min
100% Ethanol 10 min 
Solution Incubation time
2:1 Ethanol : Xylene 10-15 min
1:1 Ethanol : Xylene 10-15 min
1:2 Ethanol : Xylene 10-15 min
100% Xylene 10-15 min
100% Xylene 10-15 min
100% Xylene 10-15 min
Solution Incubation time
2:1 Xylene : Paraffin 30 min
1:1 Xylene : Paraffin 30 min
1:2 Xylene : Paraffin 30 min
100% Paraffin 1-2 hr
100% Paraffin 1-2 hr or overnight
Dehydration
Exchange ethanol with xylene
 Exchange xylene with paraffin.
Table 1: Overview of Parrafin Processing
Table 2: Dehydration Protocol
Table 3:Ethanol to Xylene Exchange
Parrafin	Processing
Begin with	Formali 	Fixed	Tissue
Rinse	Fixed	Tissue	in	PBS
Dehydrate	Tissue
Etha ol	with	Xylene
Exchange	Xylene	with	Parrafin
Tissue	is	ready	for	Embedding
Solution Incubation time
5  t l  i
7  t l  i
80  t l  i
95% Ethanol  i
 t l  i
 t l  i
100% Ethanol 10 min 
Solution Incubatio  time
2:  t l : l  i
:1 t l : l  i
:2 Ethanol : Xylene  i
 l  i
 l  i
100% Xylene 10-15 min
Solution Incubation time
2
1
:2 Xylene : Paraffin 30 min
100% Paraffin 1-2 hr or overnight
Dehydration
Exchange ethanol with xylen
 Exchange xylene with paraffin.
Table 1: Overview of Parrafin Processing
Table 2: Dehydration Protocol
Table 3:Ethanol to Xylene Exchange
Parrafin	Processing
Begin	with	Formalin	Fixed	Tissue
Rinse	Fixed	Tissue	in	PBS
Dehydrate	Tissue
Exchange	Ethanol	with	Xylene
Exchange	Xylene	with	Parrafin
Tissue	is	ready	for	Embedding
Solution Incubation time
50% Ethanol 10 min
7 % Ethanol 10 min
80  t a l 10 min
95% Ethanol 10 min
100  Ethanol 10 min
 t a l  i
100% Ethanol 10 min 
Solution Incubation time
2:  Ethanol : ylene 10-15 in
1:1 t l : l 10-15 in
1:2 Ethanol : Xylene 10-15 in
100  ylene 10-15 in
 l -  i
100% Xylene 10-15 min
Solution Incubation time
2:  ylene : araffin 30 in
1:1 l  : i  i
1:2 Xylene : Paraffin 30 min
  
100% Paraffin 1-2 hr or overnight
Dehydration
xchange ethanol with xylen
 Exchange xylene with paraffin.
Table 1: Overview of Parrafin Processing
Table 2: Dehydration Protocol
Table 3:Ethanol to Xylene Exchange
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Immersion Fixation 
10% neutral buffered formalin (NBF) is most commonly used. This fixative has 
been used unless stated otherwise. The ideal fixation time depends on the size of the 
tissue block and the type of tissue, but fixation between 18-24 hours seemed to be ideal 
for most applications. Under-fixation can lead to edge staining, with strong signal on the 
edges of the section and no signal in the middle; over-fixation can mask the epitope. 
Antigen retrieval can help overcome this masking, but if the tissue has been fixed for a 
long period of time (i.e. over a weekend), there may be no signal even after antigen 
retrieval. 
After fixation, the tissue block was embedded in paraffin, then cut in a microtome 
to the desired thickness (approximately 5 microns is ideal for IHC) and affixed onto the 
slide. Tissue sections are best mounted on positively charged slides. Once mounted, the 
slides were dried to remove any water that may be trapped under the section by leaving 
the slides vertical at incubation of the slide at 60°C for a few hours.  
 
 Paraffin Tissue Processing 
 After fixation, tissue was rinsed with PBS until fixative was completely removed. 
We then followed tables 2 -4 to obtain paraffinized tissue for embedding. Samples were 
embedded in fresh new paraffin and oriented the tissue as desired before it hardens. 
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Table 2: Dehydration Protocol 
 
Table 3: Ethanol to Xylene Protocol 
 
Table 4: Xylene to Paraffin Protocol 
 
 
Embedding 
 Tissues that were processed into paraffin, as described in Table 5, had wax added 
to the cassettes; in order to create smooth wax blocks, the wax first needed to be melted 
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After fixation, tissue was rinsed with PBS until fixative was completely removed.  
We then followed tables 2 -4 to obtain parafinized tissue for embedding.  
 
 
 
Embed in fresh new paraffin and orient tissue as desired before it hardens. 
 
Parrafin	Processing
Begin	with	Formalin	Fixed	Tissue
Rinse	Fixed	Tissue	in	PBS
Dehydrate	Tissue
Exchange	Ethanol	with	Xylene
Exchange	Xylene	with	Parrafin
Tissue	is	ready	for	Embedding
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50% Ethanol 10 min
70% Ethanol 10 min
80% Ethanol 10 min
95% Ethanol 10 min
100% Ethanol 10 min
100% Ethanol 10 min
100% Ethanol 10 min 
Solution Incubation time
2:1 Ethanol : Xylene 10-15 min
1:1 Ethanol : Xylene 10-15 min
1:2 Ethanol : Xylene 10-15 min
100% Xylene 10-15 min
100% Xylene 10-15 min
100% Xylene 10-15 min
Solution Incubation time
2:1 Xylene : Paraffin 30 min
1:1 Xylene : Paraffin 30 min
1:2 Xylene : Paraffin 30 min
100% Paraffin 1-2 hr
100% Paraffin 1-2 hr or overnight
Dehydration
Exchange ethanol with xylene
 Exchange xylene wth paraffin.
Table 1: Overview of Parrafin Processing
Table 2: Dehydration Protocol
Table 3:Ethanol to Xylene Exchange
Parrafin	Processing
Begin with	Formali Fixed	Tissue
Rinse	Fixed	Tissue	in	PBS
Dehydrate	Tissue
Etha ol	with	Xylene
Exchange	Xylene	with	Parrafin
Tissue	is	ready	for	Embedding
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5  t l  i
7  t l  i
80  t l  i
95% Ethanol  i
 t l  i
 t l  i
100% Ethanol 10 min 
Solution Incubatio  time
2:  t l : l  i
:1 t l : l  i
:2 Ethanol : Xylene  i
 l  i
 l  i
100% Xylene 10-15 min
Solution Incubation time
2
1
:2 Xylene : Paraffin 30 min
100% Paraffin 1-2 hr or overnight
Dehydration
Exchange ethanol with xylen
 Exchange xylene with paraffin.
Table 1: Overview of Parrafin Processing
le 2: Dehydration Prot col
Table 3:Ethanol to Xylene Exchange
Parrafin	Processing
Begin	with	Formalin	Fixed	Tissue
Rinse	Fixed	Tissue	in	PBS
Dehydrate	Tissue
Exchange	Ethanol	with	Xylene
Exchange	Xylene	with	Parrafin
Tissue	is	ready	for	Embedding
Solution Incubation time
50% Ethanol 10 min
7 % Ethanol 10 min
80  t a l 10 min
95% Ethanol 10 min
100  Ethanol 10 min
 t a l  i
100% Ethanol 10 min 
Solution Incubation time
2:  Ethanol : ylene 10-15 in
1:1 t l : l 10-15 in
1:2 Ethanol : Xylene 10-15 in
100  ylene 10-15 in
 l -  i
100% Xylene 10-15 min
Solution Incubation time
2:  ylene : araffin 30 in
1 1    
:2 Xylene : Paraffin 30 min
  
100% Paraffin 1-2 hr or overnight
Dehydration
xchange ethanol with xylen
 Exchange xylene with paraffin.
Table 1: Overview of Parrafin Processing
Table 2: Dehydration Protocol
Table 3:Ethanol to Xylene Exchange
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away placing the entire cassette in 58°C paraffin bath for 15 minutes.  The heat block was 
turned on one hour before adding wax to the tissue cassettes in order to melt the paraffin. 
We opened the cassette to view tissue sample and choose a mold that best corresponds to 
the size of the tissue.  A margin of at least 2 mm of paraffin surrounding all sides of the 
tissue gives the best cutting support.  The cassette lid was discarded. 
We put small amount of molten paraffin in mold, dispensing from paraffin 
reservoir and using warm forceps, transferred the tissue into mold, placing cut side down, 
as it was placed in the cassette. 
We transferred the mold to the cold plate, and gently pressed the tissue flat.  
Paraffin solidified into a thin layer, which held the tissue in position. When the tissue is 
in the desired orientation, we added the labeled tissue cassette on top of the mold as a 
backing. Hot paraffin was added to the mold from the paraffin dispenser. Thereby 
covering the face of the plastic cassette. 
Paraffin solidified within 30 minutes.  When the wax was completely cooled and 
hardened (30 minutes) the paraffin block can be easily popped out of the mold; the wax 
blocks should not stick. If the wax cracked or the tissues were not aligned well, we 
simply melted them again and started over. The block that was formed was ready for 
sectioning and was stored at room temperature. 
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Table 5: Paraffin Processing 
 
Sectioning 
Sectioning utilized a Water bath, Container with ice, Glass microscope slides, 
Microtome and blade, and an Oven. We chilled paraffin-embedded tissue blocks on ice 
before sectioning. Cold wax allows thinner sections to be obtained by providing support 
for harder elements within the tissue specimen. The small amount of moisture that 
penetrated the block from the melting ice also made the tissue easier to cut. Filled a water 
bath with ultrapure water and heated to 40-45 degrees C. 
Placed the blade in the holder, ensuring it was secure and set the clearance angle. 
The clearance angle prevents contact between the knife facet and the face of the block. 
We followed the microtome manufacturer’s instructions for guidance on setting the 
clearance angle. For Leica blades this is normally between 1 degree and 5 degrees. 
Tissues were cut at 3 degrees.  
We carefully, approached the block with the blade and cut a few thin sections to 
ensure the positioning was correct. Adjusting if necessary. We trimmed the block to 
expose the tissue surface to a level where a representative section was cut. Trimming was 
normally done at a thickness of 10-30 µm. We cut sections at a thickness of about 4-5 µm 
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Immersion Fixation 
10% neutral buffered formalin (NBF) is most commonly used. This fixative has 
been used unless stated otherwise.  
The ideal fixation time depends on the size of the tissue block and the type of 
tissue, but fixation between 18-24 hr seemed to be ideal for most applications. Under-
fixation can lead to edge staining, with strong signal on the edges of the section and no 
signal in the middle; over-fixation can mask the epitope. Antigen retrieval can help 
overcome this masking, but if the tissue has been fixed for a long period of time (i.e. over 
a weekend), there may be no signal even after antigen retrieval. 
After fixation, the tissue block was embedded in paraffin, then cut in a microtome 
to the desired thickness (approximately 5 microns is ideal for IHC) and affixed onto the 
slide. Tissue sections are best mounted on positively charged slides. Once mounted, the 
slides were dried to remove any water that may be trapped under the section by leaving 
the slides vertical at incubation of the slide at 60°C for a few hours.  
 
 Paraffin Tissue Processing 
 
Parrafin	Processing
Begin	with	Formalin	Fixed	Tissue
Rinse	Fixed	Tissue	in	PBS
Dehydrate	Tissue
Exchange	Ethanol	with	Xylene
Exchange	Xylene	with	Parrafin
Tissue	is	ready	for	Embedding
Solution Incubation tim
50% Ethanol 10 min
70% Ethanol 10 min
80% Ethanol 10 min
95% Ethanol 10 min
100% Ethanol 10 min
100% Ethanol 10 min
100% Ethanol 10 min 
Solutio Incubation time
2:1 Ethanol : Xylene 10-15 min
1:1 Ethanol : Xylene 10-15 min
1:2 Ethanol : Xylene 10-15 min
100% Xylene 10-15 min
100% Xylene 10-15 min
100% Xylene 10-15 min
Solution Incubation time
2:1 Xylene : Paraffin 30 min
1:1 Xylene : Paraffin 30 min
1:2 Xylene : Paraffin 30 min
100% Paraffin 1-2 hr
100% Paraffin 1-2 hr or overnight
Dehydration
Exchange ethanol with xylene
 Exchang  xyl ne wi hparaffin.
Table 1: Overview of Parrafin Processing
Table 2: Dehydration Protocol
Table 3:Ethanol to Xylene Exchange
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(discarding the first few sections as they were likely to contain holes caused by 
trimming). Using tweezers, we picked up the ribbons of sections and floated them on the 
surface of the water in the water bath so they would flatten out. We used tweezers to 
separate the sections. 
We use microscope slides to pick the sections out of the water bath and stored 
upright in a slide rack. We place the slide rack into an oven and allowed sections to dry 
overnight at 37 degrees Celsius. 
 
Deparaffinizing 
Deparaffinizing the sectioned slides is necessary to further analyze the tissue 
utilizing materials and reagents: Xylene, 100% ethanol, 95% ethanol, 70% ethanol, and 
50% ethanol. We placed the slides in a rack, and performed the following washes 
described in Table 6 using Coplins jar: Once the slides were washed as detailed by Table 
6, we placed slides in running cold tap water to rinse off ethanol. 
We kept the slides in the tap water until ready to perform antigen retrieval. At no 
time from this point onwards were the slides allowed to dry. Drying out would cause non-
specific antibody binding and therefore high background staining. This process is 
described in Table 6.  
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Table 6: Deparaffinization Protocol 
 
Antigen Retrieval 
In order to allow for antigen binding for techniques like IHC a buffer solution was 
needed. Buffer solutions for heat-induced epitope retrieval was comprised of Sodium 
citrate buffer (10 mM Sodium citrate, 0.05% Tween 20, pH 6.0), mixed in Distilled water 
with a volume of 1000 ml with pH adjusted to 6.0 with NaHCl. Added 0.5 ml of Tween 
20 and mix well. Could be stored at room temperature for 3 months or at 4°C for longer 
storage. 
Microwave Heat Sourced Antigen Retrieval is a common method. The use of a 
domestic microwave is inadvisable because hot and cold spots are common, leading to 
uneven antigen retrieval. Antigen retrieval times are usually longer, due to the absence of 
a pressurized environment, nearly always leading to section dissociation. A scientific 
microwave is more appropriate as most brands have onboard pressurized vessels and can 
keep the temperature at a constant 98°C to avoid section dissociation.  
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Using tweezers, we picked up the ribbons of sections and floated them on the 
surface of the water in the water bath so they would flatten out. We used tweezers to 
separate the sections. 
We use microscope slides to pick the sections out of the water bath and stored 
upright in a slide rack. We place the slide rack into an oven and allowed sections to dry 
overnight at 37 degrees Celsius. 
 
Deparrafinizing 
Materials and reagents: 
Xylene, 100% ethanol, 95% ethanol, 70% ethanol, and 50% ethanol 
Method 
We placed the slides in a rack, and performed the following washes described in 
Table 5 using Coplins jar: 
 
Once the slides were washed as detailed by Table 5, we placed slides in running 
cold tap water to rinse off ethanol. 
Solution Incubation time
Xylene 3 min
Xylene 3 min
1:1 Xylene : 100% Ethanol 3 min
100% Ethanol 3 min
100% Ethanol 3 min
95% Ethanol 3 min
70% Ethanol 3 min
50% Ethanol 3 min
Deparrafinizing Slides
Table 5: Deparrafinization Protocol
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When using this method, it is possible for the buffer to boil over, and a large 
amount of the retrieval buffer can evaporate. We were sure to watch the buffer level 
adding more buffer as necessary to prevent the slides from drying out. 
Slides were placed in a plastic rack and vessel for this procedure because standard 
glass histology staining racks and vessels will crack when heated. Materials and reagents 
for Microwave Antigen Retrieval included a (850W) microwave, microwaveable vessel 
with slide rack to hold approximately 400-500 ml or Coplin jar, and the antigen retrieval 
buffer (e.g. Tris/EDTA pH 9.0, sodium citrate pH 6.0, etc.). 
The sections were deparaffinized and rehydrated. After adding the appropriate 
antigen retrieval buffer to the microwaveable vessel. We removed the slides from the tap 
water and placed them in the microwaveable vessel inside the microwave. Boil for 20 
min from this point once the temperature has reached 98°C. (Use a non-sealed vessel to 
allow for evaporation during the boil. We were sure to monitor for evaporation and 
watched out for boiling over during the procedure and did not allow the slides to dry out). 
When 20 min elapsed, we removed the vessel and ran cold tap water into it for 10 
min. 20 min is only a suggested antigen retrieval time. Less than 20 min may leave the 
antigens under-retrieved, leading to weak staining. More than 20 min may leave them 
over-retrieved, leading to non-specific background staining and also increasing the 
chances of sections dissociating from the slides.  
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PD-L1 Immunohistochemistry 
PD-L1 protein immunohistochemistry (IHC) was performed using the monoclonal 
antibody EPR1161(2) ab174838 (Abcam, Cambridge, USA). Blocking, addition of 
secondary antibody and washing reactions were performed according to the 
manufacturer’s instructions for the Cell and Tissue Staining Kit Rabbit Kit HRP-DAB 
System (R&D Systems, Minneapolis, USA). Antigen retrieval was performed for 30 
minutes at 98°C in 0.01 mol/L sodium citrate buffer at pH 6.0. Primary antibody was 
applied for 30 minutes at a 1:50 dilution. Secondary antibody was Goat Anti-Rabbit IgG 
H&L HRP (Abcam, Cambridge, USA) at a 1:200 dilution and was applied for 15 
minutes. 
IHC Staining Protocol for Paraffin Sections 
Reagents were applied manually by pipette and the sequence of the protocol was 
adapted to an automated systems. All incubations were carried out in a humidified 
chamber to avoid drying of the tissue. Drying at any stage leads to non-specific binding 
and ultimately high background staining. The dilutions of the primary and secondary 
antibody were listed on the datasheets determined by testing a range. An Important 
consideration is that DAB is a suspected carcinogen and was disposed of according to 
laboratory guidelines additionally noted in the R&D Systems Cell and Tissue Staining 
Kit: Rabbit Kit (Catalog Number CTS005). 
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PD-L1 IHC Staining Procedure 
The IHC staining was performed as per the manufacturer’s instructions R&D 
Systems Cell and Tissue Staining Kit: Rabbit Kit (Catalog Number CTS005). Incubated 
with Abcam Anti-PD-L1 antibody [EPR1161(2)] ab174838. The samples were 
counterstained and mounted. An additional stain was performed using BenchMark 
ULTRA with VENTANA PD-L1 (SP263) Rabbit Monoclonal Primary Antibody. Both 
made by Ventana Medical Systems, Inc.  
 
Counterstain 
Immunohistochemistry counterstain for 30 seconds was performed using 
Chromogenic Mayers Hematoxylin – Nuclei Blue to violet. 
Mounting 
Mounted coverslip using Non Aqueous Mounting Medium - PermountTM (Fisher 
Scientific, Catalog # SP-15-100) or equivalent. 
Controls 
Positive controls: In order to validate the staining in our samples, we used a 
positive control. This was a section from a cell line or tissue known to express the protein 
you are detecting. A positive result from the positive control, even if the samples are 
negative, will indicate the procedure was optimized and working. It verified that any 
negative results were valid. 
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Negative controls: Used a section from a cell line or tissue sample known not to 
express the protein we were detecting. This checked for non-specific binding and false 
positive results. Recommended negative control tissues are knock down (KD) or knock 
out (KO) tissue samples.  
The antibody was optimized in order to control for isotype control and primary 
antibody control. Using the same concentration (µg/ml) for the isotype control antibody 
and the primary antibody. This determined the level of background in our sample. 
 
Hematoxylin and Eosin Staining 
Formalin fixed, paraffin embedded human tissue samples were cut to 5 μm 
sections using a Microm HM 325 microtome (Thermo Scientific, Basingstoke, UK).  To 
stain for H & E sections were rehydrated as earlier noted. The sections were then 
immersed in Haematoxylin Solution for 30 seconds. Sections were then rinsed in tap 
water and stained with 1% Eosin Solution for 5 seconds. Followed by a final rinse with 
tap water to remove excess stain, cover slips were mounted. Template slides were 
analyzed using a light microscope and tissue regions corresponding to normal/tumor 
regions were identified and marked on the slide.  
 
IHC Scoring  
Two methods were used to score immunohistochemical staining. First, PD-L1 
stained slides were assessed in a semiquantitative method by consensus of two observers 
without prior knowledge of patient clinical features. PD-L1 slides were graded according 
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to the extent of nuclear staining on a scale of 0 – 4: 0, no staining; 1,  1% staining; 2, 1–
5% staining; 3, 6–50% staining; and 4,  50% staining. Staining scores of 0 were 
considered negative, and staining scores of 1, 2, 3, and 4 were considered positive.  
Objective validation of IHC interpretation was obtained using ImageJ (ImageJ, U. 
S. National Institutes of Health, Bethesda, Maryland, USA). The number of positive 
staining cells/HPF (Magnification 40x) were counted with the segmentation threshold set 
at 50 and the RGB color bar set at 200, based on positive and negative controls. The five 
fields of greatest positive staining were selected for each sample. 
 
DAB Quantification with Color Deconvolution 
Slide analysis was performed with ImageJ – NIH. DAB quantification was 
performed on slides with hematoxylin counterstain: Downloaded the "Fiji" version of 
ImageJ from http://fiji.sc.  All subsequent steps were performed in Fiji. Opened a DAB 
image. Run Image > Color > Colour Deconvolution. 
From the Vectors pull-down, chose "H DAB" as the stain. Clicked OK in the 
Colour Deconvolution window; getting three new images.  The one with "Colour_2" in 
the title was the DAB image (Colour_1 was the hematoxylin image), we quantified the 
Colour_2 image. 
Run Analyze > Set Measurements and select "Mean gray value" and "Display 
label". Selected the Colour_2 image window. Run Analyze > Measure (or press Ctrl-m); 
a "Results" window popped up with the quantification in units of intensity. We converted 
the intensity numbers in the Results window to Optical Density (OD) numbers with the 
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following formula: OD = log (max intensity/Mean intensity), where max intensity = 255 
for 8-bit images. This quantified the average darkness of the image due to DAB 
signal.  Results would be biased if there are images without tissue because it will bring 
the average OD down.  
Creating Regions of Interest in ImageJ 
In imageJ, circle all the cells so that each one has an ROI. The ROI can be saved 
and used for the other colors you have in a different image. Click measure after circling 
each one (ctrl+T). Average the three cells with the lowest intensities, this is the 
background. Then we calculated the threshold from that as twice the background 
intensity plus 6 times the SEM of average background.   
 Obtaining the ROI for the Optical Density Statistic 
 After taking standard images (at least five frames for each sample), we performed 
quantification using ImageJ software. First defined the Regions of Interest (ROI) using 
the Polygon or the Freehand selection tool, delimiting tumor tissue from stroma or 
adjacent regions. Next we split the image into the three color channels (RGB Merge/split 
function) to obtain one image per channel. To determine the average number of cells 
present in the previously defined ROI, use the Measure option in the program’s ROI 
Manager, to assess the integrated density value (IDV) for the blue channel. 
Using the Elliptical selection tool mark at least ten representative nuclei, covering 
the different sizes and intensities throughout the ROI. Then we determined the IDV for 
all the selected nuclei and calculate the mean nucleus value. We divided the blue channel 
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IDV by the mean nucleus value. The resulting value corresponds to the average number 
of cells present in each respective ROI. 
Measure the IDV of the respective ROI in this newly created merged image and 
divide it by the average number of cells calculated before. In the case of analysis of 
tumor samples, differentiating tumor tissue from stroma or adjacent tissue is a key step 
during ROI selection to assure integer results. 
 
Statistical Methods  
Differentiation was determined for all cases by a pathologist. In order to 
determine P values for statistical significance an unpaired two-tailed Student's t-test was 
used, and P values were calculated. The significance level was set at P < 0.05. ANOVA 
was performed on samples grouped between the quality control sample and the time point 
samples. All statistical testing was undertaken using R-Studio Version 0.98.1049 
(RStudio Inc, Boston, USA). 
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RESULTS 
 
The tumor samples processed were clear cell renal carcinoma, colon 
adenocarcinoma, undifferentiated colon tumor, neuroendocrine colon tumor, and necrotic 
tissue from a renal mass. The placenta samples were positive for PD-L1 staining. The 
spread of the Optical Density Sorted by Sample and Case in a manner as shown in Figure 
1 with the graphical representation of the result in Figure 2.  
Figure 2: Spread of Optical Density by Case sorted by Sample. 
 
 
 
Optical density in regards to sample shows variability between and within each case. 
Specimens are represented by Case numbers 2, 3, 12, 14, 15, 17, 18, 19, 20, and 21. 
Kidney specimens are cases 2, 19, and 21. Colon specimens are cases 3, 18, and 20. 
Placenta specimens are cases 12, 14, 15, 17. Samples from each case were placed in 
formalin at delay intervals of zero, one, two, three, and six hours, represented 
respectively by CQ, A, B, C, and D.  
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RESULTS 
 
 
The tumor samples processed were clear cell renal carcinoma, colon 
adenocarcinoma, undifferentiated colon tumor, neuroendocrine colon tumor, and necrotic 
tissue from a renal mass. The placenta samples were positive for PD-L1 staining. The 
spread of the Optical Density Sorted by Sample and Case shown in Figure 5. 
 
In the ImageJ software, the Sample Image underwent color deconvolution with 
the set optical density vector for DAB yielding Hematoxylin, DAB, and Complimentary 
images. The DAB staining pattern placenta showed the PD-L1 was confined primarily to 
the membrane of the trophoblast cells lining the chrionic villi (Figure 4). The samples for 
colon and kidney were found to have minimal DAB staining (Figure 2 and 3). 
 
  
 
Figure shows case 21 
 
	
Figure	shows	the	distribution	of	Optical	Densities	across	Case	and	Sample	as	
measured	from	the	deconvoluted	DAB	image.		
	
	
figure :
Figur  5: Spread of Optical Density by Case sorted by Sample 
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Figure 3: PD-L1 IHC Staining of Placenta Tissue, QC Time point 
 
A. H&E Image. B. PD-L1 IHC Image. C. Hematoxylin Image. D. DAB Image. E. 
Complimentary Image. F. H&E Image G. PD-L1 IHC Image. Representative 
photomicrographs of PD-L1 immunohistochemistry staining in quality control sample 
from case 14. Arrows indicate positively stained cell membranes. Original magnification 
A – E 40x, F, G 200x magnification. 
 
Figure 3: PD-L1 IHC Staining of Placenta Tissue, QC Time point 
 
  
 
A. H&E Image. B. PD-L1 IHC Image. C. Hematoxylin Image. D. DAB Image. E. 
Complimentary Image. F. H&E Image G. PD-L1 IHC Image. Representative 
photomicrographs of PD-L1 immunohistochemistry staining in quality control sample 
from case 14. Arrows indicate positively stained cell membranes. Original magnification 
A – E 40x, F, G 200x magnification. 
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Figure 4: PD-L1 IHC Staining of Colon Tissue, QC Time point 
 
A. H&E Image. B. PD-L1 IHC Image. C. Hematoxylin Image. D. DAB Image. E. 
Complimentary Image. F. H&E Image G. PD-L1 IHC Image. Representative 
photomicrographs of PD-L1 immunohistochemistry staining in quality control sample 
from case 3. Arrows indicate positively stained cell membranes. Original magnification 
A – E 40x, F, G 200x magnification. 
  
 
Figure 4: PD-L1 IHC Staining of Colon Tissue, QC Time point 
 
  
 
 
A. H E Image. B. PD-L1 IHC Image. C. Hematoxylin Image. D. DAB Image. E. 
plimentary Image. F. H&E Image G. PD-L1 IHC Image. Representative 
t icrographs of PD-L1 immunohist chemistry staining in quality control sample 
from case 3. Arrows indicate positively stained cell membranes. Original magnification 
A – E 40x, F, G 200x magnification. 
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Figure 5: PD-L1 IHC Staining of Renal Tissue, QC Time point 
 
 
Figure 5: PD-L1 IHC Staining of Renal Tissue , QC Time point 
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Continued Figure 5: PD-L1 IHC Staining of Renal Tissue, QC Time point 
 
A. H&E Image. B. PD-L1 IHC Image. C. Hematoxylin Image. D. DAB Image. E. 
Complimentary Image. F. H&E Image G. PD-L1 IHC Image. Representative 
photomicrographs of PD-L1 immunohistochemistry staining in quality control sample 
from case 2. Arrows indicate positively stained cell membranes. Original magnification 
A – E 40x, F-I 200x magnification. 
 
In the ImageJ software, the Sample Image underwent color deconvolution with 
the set optical density vector for DAB (3,3'-diaminobenzidine) yielding Hematoxylin, 
DAB, and Complimentary images. The DAB staining pattern placenta showed the PD-L1 
was confined primarily to the membrane of the trophoblast cells lining the chorionic villi 
(Figure 3). The samples for colon and kidney were found to have minimal DAB staining 
(Figure 4 and 5 respectively). 
The staining patterns seen between the two antibodies used shows how varied 
results can be. What is clear is that the placentas exhibit no change in response to 
differing delays to fixation and antibodies used. 66.7% (100/150) positive for the Abcam 
 
 
A. H&E Image. B. PD-L1 IHC Image. C. Hematoxylin Image. D. DAB Image. E. 
Complimentary Image. F. H&E Image G. PD-L1 IHC Image. Representative 
photomicrographs of PD-L1 immunohistochemistry staining in quality control sample 
from case 2. Arrows indicate positively stained cell membranes. Original magnification 
A – E 40x, F-I 200x magnification. 
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antibody staining versus 80% (200/250) positive for Ventana antibody staining. Broken 
down further in placenta 100% (90/90) positive for the Abcam antibody staining along 
with 100% (125/125) positive for Ventana antibody staining. In kidney 6.7% (2/30) 
positive for the Abcam antibody staining versus 66.7% (50/75) positive for Ventana 
antibody staining. In colon 26.7% (8/30) positive for the Abcam antibody staining versus 
50% (25/50) positive for Ventana antibody staining. The difference in % staining 
emphasizes one of the concerns regarding the lack of comparisons between antibodies 
being found on the market as well as FDA approved.  
In the placenta, there was PD-L1 staining noted in clusters of red blood cells 
creating artifact. This artifact would affect the scoring of the PD-L1 staining in an 
automated fashion. In order to assess the positively stained areas the Threshold feature in 
ImageJ was used to identify the positively stained areas and the create selection feature 
was used to select the area yielding the optical density through the Lambert-Beer Law.  
In a few samples the pathologist made note that the staining was lighter in the 6 hours 
delayed sample as opposed to the quality control sample. The pathologist recommended 
the use of a staging system to score the PD-L1 staining. The staining was not an obvious 
observation and was not consistent. The use of automated image analysis was shown to 
be a more effective when analyzing cytoplasmic or nuclear staining patterns (Varghese, 
Bukhari, Malhotra, & De, 2014). ImageJ creates a value for the pixel intensity in the 
sample image, which is less variable than an interpretation. A mean pixel intensity was 
attained by analyzing at least five field of highest positive staining from each slide.  
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Typical differences between Automated and Pathologist scoring show the need 
for supervision in automated scoring. When a sample like in Figure 4 shows the light 
brown staining, which could represent artifact or DAB. The automated software analysis 
would count the staining as low, while a pathologist will recognize the staining as artifact 
in terms of relevancy to cancer and count the staining as negative.  The low staining in 
stroma tissue can cause the score to be decreased in automated tumor analysis. In order to 
account for this discrepancy images using higher magnification were used.  
Table 7: Abcam Descriptive Statistics  
 
 
 
Utilizing the software the Abcam PD-L1 antibody stain was not found to have any 
significant differences between the quality control and the 6-hour time point (See Table 
7). However, what presented was a lower mean optical density in the 6-hour time point 
versus the quality control in all sample groups. When performing this analysis amongst 
the Ventana PD-L1 antibody stain, all sample groups were found to be insignificant 
between the quality control sample and the 6-hour time point (See Table 8).  
Importantly the 6-hour delay to fixation sample for the total and kidney samples 
had a higher mean optical density than the quality control samples, the colon samples 
VENTANA
Sample Mean St dev St Error p value N
Total QC 0.1359 0.0917 0.0290 10
Total D 0.1399 0.1217 0.0385 10
Colon QC 0.5178 0.1069 0.0617 4
Colon D 0.4818 0.1136 0.0656 4
Kidney QC 0.2229 0.0173 0.0100 3
Kidney D 0.2996 0.0543 0.0314 3
Placenta QC 0.6178 0.0055 0.0028 3
Placenta D 0.6178 0.0597 0.0299 3
ABCAM
Sample Mean St dev St Error p value N
Total QC 0.4068 0.0213 0.0290 14
Total D 0.3356 0.0236 0.0385 14
Colon QC 0.0577 0.0159 0.0617 4
Colon D 0.0368 0.0110 0.0656 4
Kidney QC 0.0495 0.0145 0.0100 3
Kidney D 0.0284 0.0128 0.0314 3
Placenta QC 0.2996 0.0204 0.0028 7
Placenta D 0.2704 0.0245 0.0299 7
0.5637
0.7349
0.8988
0.9007
0.4810
0.9998
0.5400
0.5657
 42 
found the quality control group to have a higher optical density than the 6 hour delay to 
fixation group, and in the placenta samples the optical densities were the same while the 
standard deviation was greater amongst the 6-hour delay to fixation group. After further 
analysis it cannot be ruled out that the differences between the quality control and 6-hour 
time point groups are random. The trend albeit insignificant seen in the Abcam data did 
not carry over into the Ventana data suggesting the IHC staining of PD-L1 is not affected 
by a delay to fixation of 6 hours.   
Table 8: Ventana Descriptive Statistics 
 
 
 
Quantification analysis if immunohistochemistry is controversial. Assessing the 
area stained on a slide can yield areas of good and poor staining (Jaraj et al., 2009). 
Typically there is higher staining near the edges of the slide, which is a problem of 
reproducibility in scoring amongst pathologists (Gavrielides, Gallas, Lenz, Badano, & 
Hewitt, 2011). This study used of ImageJ, which intended to assess the data quality 
coming out of automation, as this can impact clinical practice. It is important to note that 
the use of supervised automated tools eliminates the biases of the manual observations 
VENTANA
Sample Mean St dev St Error p value N
Total QC 0.1359 0.0917 0.0290 10
Total D 0.1399 0.1217 0.0385 10
Colon QC 0.5178 0.1069 0.0617 4
Colon D 0.4818 0.1136 0.0656 4
Kidney QC 0.2229 0.0173 0.0100 3
Kidney D 0.2996 0.0543 0.0314 3
Placenta QC 0.6178 0.0055 0.0028 3
Placenta D 0.6178 0.0597 0.0299 3
ABCAM
Sample Mean St dev St Error p value N
Total QC 0.4068 0.0213 0.0290 14
Total D 0.3356 0.0236 0.0385 14
Colon QC 0.0577 0.0159 0.0617 4
Colon D 0.0368 0.0110 0.0656 4
Kidney QC 0.0495 0.0145 0.0100 3
Kidney D 0.0284 0.0128 0.0314 3
Placenta QC 0.2996 0.0204 0.0028 7
Placenta D 0.2704 0.0245 0.0299 7
0.5637
0.7349
0.8988
0.9007
0.4810
0.9998
0.5400
0.5657
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and improves the throughput of analysis. There are only a few steps involved in analysis, 
which can easily be automated.  
  In our model, optical density is the response variable whereas the explanatory 
variables are Case and Sample. The Case is the source of the resected sample, while the 
Sample is indicative of the time point of delay to fixation. QC was placed immediately 
into formalin, A was placed in formalin at one hour, B was placed in formalin at two 
hours, C was placed in formalin at three hours, and D was placed in formalin at 6 hours. 
Given this, the null hypothesis was that the means would be equal meaning there would 
be no relationship between optical density with the case and/ or sample. The Alternative 
hypothesis would be that not all the means are equal so a relationship between Optical 
Density with Sample and Case could probably exist.   
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Table 9: Analysis of Variance 
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 The quantification of PD-L1 was repeated and the results of the Two Factor 
ANOVA showed significance between cases. Yet found no significance between samples 
	Df				 Sum	Sq				 Mean	Sq	 F	value 											Pr(>F)		
Case							 1 0.0023693 0.0023693 5.5363 0.02755 *
Sample				 1 0.0001864 0.00018644 0.4357 0.51578
Residuals			 23 0.0098431 0.00042796
Signif.	codes:		
0	‘***’	0.001	‘**’	0.01	‘*’	0.05	‘.’	0.1	‘	’	1
	Df				 Sum	Sq				 Mean	Sq	 F	value 											Pr(>F)		
Case							 1 0.030018 0.0300178 9.1142 0.00421 **
Sample					 4 0.008773 0.0021932 0.6659 0.61906
Residuals													44 0.144915	 0.0032935
Signif.	codes:		
0	‘***’	0.001	‘**’	0.01	‘*’	0.05	‘.’	0.1	‘	’	1
	Df				 Sum	Sq				 Mean	Sq	 F	value 											Pr(>F)		
Case						 1 0.029286 0.0292859 11.9476 0.002051 **
Sample				 4 0.017964 0.0044911 1.8322 0.155532
Residuals			 24 0.058829 0.0024512
Signif.	codes:		
0	‘***’	0.001	‘**’	0.01	‘*’	0.05	‘.’	0.1	‘	’	1
	Df				 Sum	Sq				 Mean	Sq	 F	value 											Pr(>F)		
Case							 1 0.0010942 0.00109424 0.554 0.469
Sample				 4 0.0024661 0.00061652 0.3122 0.8651
Residuals	 14 0.0276505 0.00197504
Response:	Optical	Density
Response:	Optical	Density
Analysis	of	Variance	Table	of	Hand	Stained
Analysis	of	Variance	Table	All	Data	Machine	Stained
Analysis	of	Variance	Table	of	Cancer	Cases	Machine	Stained
Analysis	of	Variance	Table	of	Placenta	Cases	Machine	Stained
Response:	Optical	Density
Response:	Optical	Density
Table 7: Analysis of Variance Tables
a
b
c
d
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 The quantification of PD-L1 was repeated and the results of the Two Factor 
ANOVA (analysis of variance) showed significance between cases. Yet found no 
significance between samples (Table 9). The hand stained specimens found a significant 
difference, p value of 0.028 between the Cases, which was also seen in the machine 
stained specimens with a p value of 0.004. Interestingly when the machine stained 
specimens were broken down between the placenta and cancer cases the significance was 
lost in the placenta cases and remained in the cancer cases with a p value of 0.002.  
 Further Post Hoc analysis through the Tukey multiple comparison of means at a 
95% family-wise confidence level found that there were no means that were significantly 
different between the Samples with p-values ranging from 0.71 to 1.0 (Table 10). More 
importantly the trends that become clear from analysis are that PD-L1 expression does 
not significantly change due to a delay to fixation and in non-control cases like cancer the 
variation seen within the sample may not be statistically significant but the variation seen 
between cases is not likely due to chance and is significant.  ANOVA in this instance 
showed that the variation between Case means is likely due to true differences about the 
population means rather than sampling variation.  
ANOVA showed that there is a potential relationship between Optical Density 
with Case and Sample. Yet in this instance the evidence is not strong enough to conclude 
that the null hypothesis cannot be rejected.  
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Table 10: Tukey Means Analysis 
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Sample 	diff			 		lwr							 	upr 									p	adj
B-A		 0.00 -0.07 0.07 1.00
C-A		 -0.01 -0.08 0.07 1.00
D-A			 0.03 -0.05 0.10 0.82
QC-A		 0.02 -0.05 0.10 0.91
C-B	 0.00 -0.08 0.07 1.00
D-B			 0.03 -0.05 0.10 0.82
QC-B		 0.02 -0.05 0.10 0.90
D-C			 0.03 -0.04 0.11 0.71
QC-C	 0.03 -0.05 0.10 0.82
QC-D -0.01 -0.08 0.07 1.00
Fit:	aov(formula	=	Statistic.OD	~	Case	+	Sample,	data	=	alla)
				95%	family-wise	confidence	level
		Tukey	multiple	comparisons	of	means
Table 8: Tukey Means Analysis
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DISCUSSION 
 There were four cases of kidney cancer, three cases of colon cancer, and 14 
placenta cases (See Table 1). For all cases there was a Quality Control sample placed 
immediately into formalin. The remaining pieces were placed into humidity chambers at 
ambient room temperature for time points of up to one hour, two hours, three hours, and 
six hours. The placenta cases, 4-17, were all described as normal. The renal cases were 1-
2, 19, and 21. The colon cases were 3, 18, and 20. 
 In order to determine the MSI status of the colon cancers, case 3 was found to be 
MSI low, with the D2 marker being positive while the markers BAT25, BAT26, D5-
APC, and D17 were negative. Cases 18 and 20 were found to be MSS. (See Table 11). 
This is important as PD-L1 is typically found in 47% of colorectal cancer cases, while 
being more common in MSI high cases than MSI low and MSS cases. In general the MSI 
high cases are quite rare in the total colorectal cancer population and would appear to 
benefit from PD-L1 therapy (Gatalica et al., 2014). Given that PD-L1 is expressed in 
approximately 57% of renal tumors with poor prognostic outcomes (Leite et al., 2015), it 
is no wonder that PD-L1 has an important prognostic value and is proving to be a good 
treatment target.  
   
 
 
 
 
 
 
 
 
 
 48 
 
 
  Table 11: MSI/MSS Status and PD-L1 Expression 
 
 
Droeser et al. described PD-L1 as being expressed in the mucosal epithelial cells 
in normal colon tissue (Droeser et al., 2013). Additionally in MSS colorectal cancer 
samples: 37% were stained strongly positive for PD-L1, 60% of the samples had weak 
staining, and 3% were absent of stain (Droeser et al., 2013). Droeser et al. found MSI 
colorectal cancer samples had similar results with 29% were stained strongly positive for 
PD-L1, 64% % of the samples had weak staining, and 2.7% were absent of stain (Droeser 
et al., 2013). In a study by Zhu et al., PD-L1 was found in the cell cytoplasm and 
membranes of Serrated Adenocarcinoma tumor cells (Zhu et al., 2015). Additionally Zhu 
et al. found that high staining was associated with lymph node metastasis and distant 
metastasis although multivariate analysis did not show PD-L1 to be an independent 
prognostic factor (Zhu et al., 2015).  
Kim et al. found MSI high colorectal cancers are closely associated with high 
expression of PD-L1 (Kim, Park, Cho, Lee, & Kang, 2016). Le et al. confirmed this by 
finding MSI cancers contain more lymphocyte infiltrates (Le et al., 2015). Le et al. also 
Molecular Profile 3 18 20
MSI status MSI Low MSS MSS
D2 + - -
BAT25 - - -
BAT26 - - -
D5-APC - - -
D17 - - -
PD-L1 Status - + +
Colon Specimen
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found that membranous PD-L1 expression occurred in MSI colorectal cancers in addition 
to the TIL’s and tumor associated macrophages (Le et al., 2015). The MSI tumors contain 
a high mutational load allowing for the creation of tumor specific neoantigens, 
approximately 10-50 times that of MSS tumors (Llosa et al., 2015).  MSI colorectal 
tumors stimulate the immune system, which is supported by the presence of TIL’s. 
The expression of immune checkpoint ligands, like PD-L1, counters the active 
immune microenvironment to resist immune detection and elimination (Llosa et al., 
2015). The responsiveness of the anti-PD therapies is due to the increased presentation of 
mutation-associated neoantigens due to the MSI (Le et al., 2015). MSI status appears to 
be a classical example of adaptive resistance where Th1 and CTL cells present in the 
microenvironment induce the expression of PD-L1 (Jacobs, Smits, Lardon, Pauwels, & 
Deschoolmeester, 2015).  
The immune system is tasked with trying to keep a balance between eliminating 
pathogenic microbes and self-preservation. Within the adaptive arm, T cells are tasked 
with this function and are regulated both positively and negatively through the B7/CD28 
family of molecules. Typical T cell activation requires two signals, the first being the 
TCR recognizing a peptide carrying MHC (major histocompatibility complex) on an 
antigen presenting cell. The second antigen independent signal is supplied by the B7 
family members on the T cell. Without this second signal the T cell becomes 
unresponsive or anergic (Hofmeyer, Jeon, & Zang, 2011).  
Programmed death-1 is one of the B7 family members presented on T cells. Its 
ligand Programmed death Ligand-1 is presented on tumor cells, as well as B cells, 
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monocytes, (Dong, Zhu, Tamada, & Chen, 1999). Dendritic cells (Carter et al., 2002) 
macrophages (Yamazaki et al., 2002), and peripheral tissue like heart lung placenta lung 
kidney and liver (Dong et al., 1999). INF-gamma is a known regulator for PD-L1 
expression (Lee et al., 2006) induces the transcription factor IRF 1 that binds to 
regulatory sites in the PD-L1 gene inducing transcription.  
The binding of PD-1 and PD-L1 causes a decrease in T cell proliferation and the 
production of effector cytokines like IL-2 and INF-gamma (Carter et al., 2002). While 
Brown showed that when blocking the interaction the proliferative capacity of T cells 
increased (Day et al., 2006).  The pathway is utilized by both the HIV (human 
immunodeficiency virus) and hepatitis virus to exhaust CTL’s  allowing the virus to 
escape and persist (Kantzanou et al., 2003). HBV (hepatitis B virus) CTL’s were found to 
express PD-1 when administered anti-PD-1 exhaustion was reversed (Boni et al., 2007). 
Bacterial infections such as H. pylori were shown to upregulate PD-L1 on 
dendritic cells (Mitchell et al., 2007) and epithelial gastric cells (Das et al., 2006) with 
gastric CD4 T cells expressing higher levels of PD-1 (Wu et al., 2011).  It was found that 
PD-1/PD-L1 blockade was shown to enhance pathogen specific Tregs (Franceschini et 
al., 2009). 
Neutrophils are the largest leukocyte population with essential effector function of 
the innate immune system in the host defense against pathogens with a developing role in 
the adaptive arm of the immune system (Amulic, Cazalet, Hayes, Metzler, & Zychlinsky, 
2012). Neutrophils co-localize with T cells at sites of infection and migrate to the 
draining lymph node where they are involved in the induction and regulation of immune 
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responses. Neutrophils have been able to negatively regulate T cell function through 
Reactive oxygen species (ROS) and arginase-1 (Mantovani, Cassatella, Costantini, & 
Jaillon, 2011).  
Bowers showed that neutrophils in the blood of HIV infected individuals express 
increased PD-L1 that bind to T cells suppressing their effector functions(Bowers et al., 
2014). Showing PD-L1 expression is induced by HIV-1 virons, INF-alpha, TLR-7/8 and 
lipopolysaccharide (LPS) to support the T cell exhaustion and immune suppression. INF-
gamma stimulated neutrophils also express PD-L1 (de Kleijn et al., 2013). Again this 
supports the limit of immune activation as neutrophil mediated immune suppression is 
beneficial in acute sepsis (Hotchkiss, Coopersmith, McDunn, & Ferguson, 2009) or acute 
infection (Fujisawa, 2008). However the problem is associated with the long term 
suppression of T cell function in the case of Tumor or Viral infection.  
T cell exhaustion in HIV-1 infection is associated with increased PD-1 expression 
on the surface of CD4 and CD8 t cells. Blocking the PD-L1 and PD-1 pathway in chronic 
simian immunodeficiency virus (SIV) infection represses the function of SIV specific 
cellular and humoral immune response, viral control, and reduces immune activation 
(Dyavar Shetty et al., 2012). Thereby supporting the therapeutic blocking of PD-1/PD-l1.  
Immunotherapy is intended to restore the immune system’s natural defense and ability to 
respond and to eliminate abnormal antigens (Forde, Reiss, Zeidan, & Brahmer, 2013). 
Passive immunotherapy is designed with the intent of delivering antibodies to tumor 
specific antigens that then mark the cell for destruction while active immunotherapy aim 
 52 
to modify the endogenous immune response, i.e. a vaccine (Topalian, Drake, & Pardoll, 
2012). 
An explanation for the lack of results in next generation vaccines has been the 
incomplete understanding of the immune system and the mechanisms tumors use to avoid 
immune detection and eradication. Yoshiko et al. have provided evidence that PD-L1 
expression by tumor cells prevents CTL effector function in vitro and increases 
tumorgenecity in vivo (Iwai et al., 2002). Indicating that PD/PD-l blocking can provide 
high yield results by reversing the tumor microenvironment enhancing the endogenous 
antitumor response (He, Hu, Hu, & Li, 2015).  
Studies have shown that combination therapy involving PD-1/PD-l1 inhibitors 
were most effective when combined with therapies that activate the immune system (Bald 
et al., 2014). Radiotherapy has also been associated with an increase of PD-L1 expression 
on tumor cells (Dovedi et al., 2014). With respect to using PD-L1 as a biomarker shows 
it’s difficult to ascertain its utility, as it is an inducible surface molecule with tumors 
being heterogeneous in expression.  
 To complicate matters the gut microbiota has been shown to influence the 
systemic health and immune responses (Hooper, Littman, & Macpherson, 2012). The 
microbiota has been shown to have an effect on the development of cancer and the 
response to chemotherapeutics (Iida et al., 2013). Sivan et al. 2015 has shown that the 
CD8+ T cell infiltration was improved with the transplantation of feces saw reduced 
tumor growth. They went on to show that the dosing of fecal material and anti PD-L1 
significantly reduced the growth rate of established tumors (Sivan et al., 2015). Sivan et 
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al. found Bifidobacteria modulate the activation of dendritic cells and support the effector 
function of CD8+ T cells (Sivan et al., 2015). The idea that commensal bacteria 
influences cancer outcomes is not new but the emerging trend is the realization that the 
gut microbiota can have important implications for health outcomes and can be 
manipulated for health purposes.  
One of the most important principles of the PD therapy is the ability to localize to 
the tumor site due to the expression of PD-L1 within the tumor microenvironment 
defining the location of action. This appears to bring about a shift in therapy design 
intended to identify other immune targets modulated by the tumor to identify 
abnormalities allowing for selective action at the tumor site. It can be considered an 
immune response failure if a tumor or cancer continues to late stages. PD therapy studies 
have indicated that this could be repaired and allow the immune response to eradicate the 
tumor (Sznol & Chen, 2013).  
Cancer is a chronic, polygene, inflammatory mediated disease. The formation of 
the tumor microenvironment creates an environment that allows the tumor to escape 
immune detection and propagates its survival. One way this occurs is by the tumor cells 
and stroma cells upregulating PD-L1 promoting suppression of the immune system, 
leading to the development of the adaptive resistance hypothesis.  
Patients with greater PD-L1 positive tumors benefit more greatly than those who 
are negative. There is no standard test or quantification method for PD-L1 making it 
difficult to compare results from the trials. Roche has found a greater significance of PD-
L1 expression in the tumor infiltrate with response to therapy than the tumor expression 
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of PD-L1 (Herbst et al., 2014). PD-L1 expression is measured by IHC and is variable at 
different sites of the disease and at different time points during the course of the disease. 
Interestingly the expression level of PD-L1 and the mutation burden are able to predict 
the success of treatment. (Rizvi et al., 2015).  
PD-1/PD-L1 pathway regulates immune suppression by activating apoptosis in 
active T cells where blocking PD-L1 has been shown to reduce apoptosis in activated T 
cells (Curiel et al., 2003). This pathway also facilitates the anergy and exhaustion as seen 
with tumor development in cases of chronic infection due to over expressed PD-1 on T 
cells as blocking this pathway results with increased proliferation secretion and 
cytotoxicity (Barber et al., 2006). PD-1/PD-L1 also enhances the function of Tregs by 
promoting the generation of Tregs in peripheral tissue (Francisco et al., 2009). 
 The co-inhibitory pathways play a role in protection against the immune system. 
PD-L1 is upregulated on immune cells and cancer cells due to Toll like Receptor (TLR) 
or INF-gamma signaling pathways. The extrinsic stimuli acting via these pathways 
regulate the nuclear translocation of transcription factors to the PD-L1 promoter 
(Ritprajak & Azuma, 2015). Additionally intrinsic factors due to cancer changes affect 
the expression of PD-L1. Increased PD-L1 expression was seen with the increased 
proliferative expression of Ki-67 (Ghebeh et al., 2007), activating EGFR mutations 
(Azuma et al., 2014), as well as the decreased expression of PTEN (Parsa et al., 2007).  
In this sense it is important to consider the cause of expression in various tissues as 
increased expression is not only due to extracellular cytokines but also due to intrinsic 
changes associated with cancerous changes like epithelial mesenchymal transition and 
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tumorigenesis. In these instances the higher PD-L1 expression will allow for the evasion 
of immune attack through the PD-1:PDL1 immune checkpoint pathway.  
A fertilized egg will develop into an embryo. The embryo at the day 6 blastocyst 
stage has hatched from the zona pellucida allowing for the trophoblast to invade the 
uterine wall. The inner cell mass will develop into the fetus and the trophoblast will 
develop into the placenta where it has nutritional functions and diverse endocrine 
functions. It is location of the interaction between the fetal and maternal systems. PD-L1 
is expressed in the lining of the chorionic villus to reduce immune attack and promote 
tolerance of the fetus.  
The varying expression patterns among tumor types reflects the susceptibilities of 
tumor cells to cytokines and other stromal factors in the tumor microenvironment (Taube 
et al., 2015). It has been shown that certain types of Renal cell carcinoma express PD-L1 
on tumor cells and tumor cell infiltrates, while colon cancer rarely express PD-L1 on the 
tumor cells.  
There are currently two companion diagnostics approved for the PDL1 biological 
pathway that are distinct in regards to its clinical pharmacology due to their independent 
development processes. Pave the way for practice guideline development. Given this 
variability it is increasingly difficult to use PD-L1 IHC as a diagnostic test as more 
information is needed to see the clinical correlations. Some pitfalls include accurate 
measurement and scoring of the PD-L1 protein. Importantly it remains unclear if PD-L1 
expression is related to patient survival and therapeutic response. 
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CONCLUSIONS 
Delays to fixation are seen as variables that can often have deleterious effects on 
the expression of biomarkers. In breast tissue, estrogen receptor analysis requires a 
window of fixation to be adopted in order to allow for the variation to decrease across lab 
to lab. In this study the membranous expression of PD-L1 was not seen to be significantly 
susceptible to the decay due to delay to fixation in the placenta or cancer tissues. In effort 
to better allow the less variation between laboratories and even person-to-person within a 
lab supervised automated Immunohistochemistry analysis was adopted and 
recommended. Despite the interesting results from the ANOVA analysis, which shows a 
potential relationship between the Optical Density with the Case and Sample, there is not 
enough evidence to rule out variability in the sample. Some of the confounding factors 
were attempted to mitigate the effects of things like the difficulty of staining, the 
variation in sample, as well as the limitations of the software and technology used to 
obtain the Optical Density measurements.   
Antigens of interest in formalin fixed paraffin embedded tissues are detected by 
an antibody detection system. These systems are difficult to quantify due to the level of 
staining not necessarily representing the quantity of antigen present. Antigens must 
undergo retrieval and this process has been known to vary from practice to practice 
(Kanai, Nunoya, Shibuya, Nakamura, & Tajima, 1998). This being said it is widely held 
that the darker a staining spot is the more precipitate is bound to antigen in that spot. In 
this sense laboratories have made efforts to quantify the staining under bright field 
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microscopy. Here an inverse relationship exists between the amount of antigen retrieved 
and the numerical intensity value.  
In cases where the antibodies have nonspecific binding and the samples cannot be 
restained, a background subtraction threshold is warranted. Normalizing the values of the 
Regions of Interest is begun with identifying background or artifact staining and 
determining the reciprocal intensity for background subtraction. This method of 
mathematical manipulation is not without controversy and has not been fully validated on 
a large-scale basis. In general the quantification of chromogen intensity is developing as 
more sophisticated models and mathematics are being applied to automate the process in 
effort to reduce human error.  
 Applying this technique to the emerging PD/PD-L axis will prove useful for 
determining the appropriateness of targeted immunotherapies. These targeted 
immunotherapies will likely become more commonplace alongside traditional 
chemotherapeutics due to their safety and efficacy.  
 The immune system is a complex system with implications of health and survival. 
The immune priming begins at a young age and as the hygiene hypothesis dictates 
microbial interactions develop normal functioning components that can determine self 
and tolerance. Both microbes and cancer have adapted to hijack the immune system in 
effort of evasion have utilized the PD/PD-L axis. While it is easy to understand that 
cancer utilizes this evasion technique the novelty of microbial burdens are now just 
beginning to be understood as a way to boost immunotherapy responses and improve the 
health of populations.   
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